Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.

Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.

Abstract: Provided is antitumor therapy using oncolytic viruses which exhibits an excellent antitumor effect and has reduced adverse effects. An antitumor agent, comprising a combination of an oncolytic virus and an anticancer agent selected from the group consisting of oxaliplatin, an anticancer plant alkaloid, and an antimetabolite.

Abstract: The present invention includes methods for treating a proliferative disorder in a subject with mutated or constitutively active FLT3 in a subject relapsed/refractory to one or more prior tyrosine kinase inhibitors comprising: obtaining a tumor sample from the subject that is relapsed/refractory to one or more prior tyrosine kinase inhibitors; measuring expression of mutated or constitutively active FLT3 mutant in the tumor sample; and administering to the subject a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof sufficient to treat the proliferative disorder.

Abstract: The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).

Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

Abstract: The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

Abstract: Novel compositions and methods of using the compositions to treat triple negative breast cancer are presented. 4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide has been shown to downregulate the expression of several genes associated with TNBC such as amphiregulin (AREG), epiregulin (EREG), inhibitor of DNA binding 1 (ID1), inhibitor of DNA binding 3 (ID3), killer cell lectin like receptor C3 (KLRC3), cyclooxygenase-2 (COX2), and intercellular adhesion molecule 1 (ICAM-1). In addition, the compound has been shown to downregulate the oncostatin M(OSM) signaling pathway.

Abstract: Methods for treating pediatric patients with systemic mastocytosis are described by administering midostaurin.

Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

Abstract: Inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.

Abstract: The present disclosure provides a method for controlling Fusarium oxysporum f. sp. cubense tropical race 4 (Foc TR4). The present disclosure mainly aims to solve the problem of effectively inhibiting the Foc TR4, but the existing fungicides cannot effectively inhibit the Foc TR4 without damage to banana plants. By treating with the fungicide disclosed by the present disclosure, the growth of the Foc TR4 can be limited, and there is no adverse effect on banana plants.

Abstract: A method for producing acrylonitrile, having: a catalyst treatment step of preparing a composite metal oxide catalyst including molybdenum, bismuth, and iron and including 50 ppm or more of carbon; and a vapor-phase catalytic oxidation step of subjecting propylene to ammoxidation reaction using the composite metal oxide catalyst to produce acrylonitrile.

Abstract: Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.

Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.